<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03466827</url>
  </required_header>
  <id_info>
    <org_study_id>TET-SEL</org_study_id>
    <nct_id>NCT03466827</nct_id>
  </id_info>
  <brief_title>Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma</brief_title>
  <acronym>TET-SEL</acronym>
  <official_title>A Phase II Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumour (TET) Progressing After Primary Chemotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Morten Mau-Soerensen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GSO Global Clinical Research BV</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karyopharm Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to determine the efficacy of selinexor in adults with TETs determined
      by overall response rate (RECIST 1.1) in two parallel cohorts of patients with advanced
      thymomas or thymic carcinomas. The study is an international, multicenter, open label phase
      II trial using Simons two stage design. The study population is adults with histologically
      confirmed, advanced, inoperable TETs who are progressing after treatment with least one
      platinum containing chemotherapy regimen.

      This study is comprised of 2 similar phase II tirals, one running in EU (25 patients) and one
      running in US (25 patients).

      There are two study arms:

      Arm A: Thymoma

        -  Stage 1: 15 patients

        -  Stage 2: 10 patients

      Arm B: Thymic carcinoma

        -  Stage 1: 15 patients

        -  Stage 2: 10 patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Not provided
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 12, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>24 months</time_frame>
    <description>To determine the overall response rate according to RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>6 months</time_frame>
    <description>To determine six months progression free survival of patients with TET treated with selinexor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>24 months</time_frame>
    <description>The number of adverse events as determined by Common Terminology Criteria for Adverse Events (CTCAEs) version 4.03</description>
  </secondary_outcome>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Thymoma</condition>
  <condition>Advanced Thymic Epithelial Tumour</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor</intervention_name>
    <description>Selinexor 60 mg oral tablets will be administered twice weekly, either Monday/Wednesday or on Tuesday/Thursday or on Wednesday/Friday in a 3-weeks-on and 1-week-off Schedule.</description>
    <other_name>KPT-330</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed advanced TET (thymoma or thymic carcinoma)

          -  Inoperable per local Investigator (Masaoka Stage III or IV)

          -  Progression after treatment with least one platinum containing chemotherapyregimen

          -  Measurable disease (RECIST 1.1)

          -  Age ≥18 years

          -  ECOG PS &lt;2

          -  Patients must have recovered from the toxic effects of prior therapy at the time of
             initiation of the study drug unless toxicity is stable.

          -  A 4 weeks interval from any investigational agents or cytotoxic chemotherapy to start
             of study is required

          -  Signed informed consent

          -  Adequate bone marrow function and organ function:

               -  Hematopoietic function: total white blood cell count (WBC) ≥ 3000/mm³, absolute
                  neutrophil count (ANC) ≥ 1500/mm³, platelet count ≥ 100,000/mm²

               -  Hepatic function: bilirubin &lt; 1.5 times the upper limit of normal (ULN), ALT &lt;
                  2.5 times ULN or ALT &lt; 5.0 times ULN in the presence of liver metastases

               -  Creatinine clearance &gt; 30 ml/min according to Cockcroft-Gault

          -  Patients of childbearing potential must agree to use adequate birth control during and
             for 3 months after participation in this study

        Exclusion Criteria:

          -  No significant medical illness that in the investigator's opinion cannot be adequately
             controlled with appropriate therapy or would compromise the patient's ability to
             tolerate this therapy, including

               -  Unstable cardiovascular function

               -  Known active hepatitis A, B, or C infection; or known to be positive for HCV RNA
                  or HBsAg (HBV surface antigen)

               -  Markedly decreased visual acuity

               -  Active infection requiring intravenous antibiotics

          -  Pregnancy or breast-feeding

          -  Symptomatic brain metastasis requiring corticosteroids

          -  Uncontrolled autoimmune disorders. Patients with autoimmune disorders under control on
             medication may be included. Patients with pure red cell aplasia may be included if
             haemoglobin levels are relatively stable on transfusions or medication

          -  Any other cancer (excluding radically operated localised squamous skin cancer) with
             clinical activity within the last 2 years

          -  Significantly diseased or obstructed gastrointestinal tract, malabsorption,
             uncontrolled vomiting or diarrhea or inability to swallow oral medications

          -  No dehydration of NCI-CTCAE grade ≥ 1

          -  Serious psychiatric or medical conditions that could interfere with treatment.

          -  No history of organ allograft

          -  No concurrent therapy with approved or investigational anticancer therapeutics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morten Mau-Soerensen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Morten Mau-Soerensen, MD, PhD</last_name>
    <phone>+45 3545 0879</phone>
    <email>paul.morten.mau-soerensen@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristoffer S Rohrberg, MD, PhD</last_name>
    <phone>+45 3545 6353</phone>
    <email>kristoffer.staal.rohrberg@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morten Mau-Soerensen, MD, PhD</last_name>
      <phone>+ 45 3545 0879</phone>
      <email>morten.mau-soerensen@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Kristoffer S Rohrberg, MD, PhD</last_name>
      <phone>+45 3545 6353</phone>
      <email>kristoffer.staal.rohrberg@regionh.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Gedske Daugaard, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marylise Ginoux, Professor</last_name>
      <email>marylise.ginoux@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Marylise Ginoux, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intitut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas Girard, Professor</last_name>
      <email>nicolas.girard2@curie.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas Girard, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intitut Gustave Roussy</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Benjamin Besse, Professor</last_name>
      <email>benjamin.besse@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>Benjamin Besse, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2018</study_first_submitted>
  <study_first_submitted_qc>March 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2018</study_first_posted>
  <last_update_submitted>March 9, 2018</last_update_submitted>
  <last_update_submitted_qc>March 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Morten Mau-Soerensen</investigator_full_name>
    <investigator_title>Chief Physician, MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thymoma</mesh_term>
    <mesh_term>Thymus Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

